BT Slingsby is Founder and Managing Director with Catalys Pacific. He founded Catalys Pacific to transform life-sciences innovation using transpacific partnership. BT is a physician-scientist and biotechnology entrepreneur leading the company creation efforts for the firm. Prior to Catalys Pacific, he founded and served as CEO and Executive Director of the Global Health Innovative Technology (GHIT) Fund – the world’s first public-private fund focused on the development of new medicines for low- and middle-income countries — with anchor investments from Astellas, Daiichi Sankyo, Eisai, Shionogi, Takeda, the Bill & Melinda Gates Foundation, and the Government of Japan. Previously, BT worked at Eisai Co. & Ltd. on global strategy. BT graduated from Brown University with honors, earned his MPH and PhD from Kyoto University and the University of Tokyo, and received his MD with honors from the George Washington University. In recognition of his contributions to global health, he has been awarded a Foreign Ministry Commendation from the Government of Japan. His work has been featured in the Economist, Financial Times, Forbes, CNBC Squawk Box, and the New York Times. BT is an author on over 50 peer-reviewed articles on medicine and public health, and formerly served as a Visiting Professor at Keio University, Kyoto University and Osaka University and Visiting Research Fellow at the University of Tokyo.